All In MedTech

FDA Clearance Tracker · K253801

ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this decision)Source: openFDAMethods & limitations

510(k)First of its product codeBreakthrough

Decided

Apr 7, 2026

Substantially Equivalent

Time to decision

130 days

Received Nov 28, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K253801
Device name
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)
Applicant
Anumana, Inc.
Applicant location
Cambridge, MA
Received
Nov 28, 2025
Decided
Apr 7, 2026
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 870.2380

Every decision under product code SHP

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SHP (Cardiac Amyloidosis Machine Learning-Based Notification Software).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Anumana, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.